Osimertinib combined with chemotherapy as fi rst-line treatment in EGFR-mutant advanced NSCLC patients: The fi rst real-world analysis in China

被引：0
|
作者：
Ji, W. [1 ]
Yu, Y. [1 ]
Ai, X. [1 ]
Chen, Z. [1 ]
Zhou, Z. [1 ]
Li, Z. [1 ]
机构：
[1] Shanghai Liao Tong Univ, Shanghai Chest Hosp, Med Oncol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.732
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
699P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Real-world outcomes of first-line osimertinib for EGFR mutated advanced NSCLC patients in China: Interim analysis of the FLOURISH study
    Zhou, J.
    Zhou, J.
    Zheng, J.
    Wang, K.
    Tang, K.
    Lu, D.
    Cui, J.
    Zhu, D.
    Wang, Y.
    Zhao, Y.
    Xing, L.
    Ding, L.
    Shi, X.
    Shen, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1065 - S1065
  • [22] First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
    Ji, W.
    Jiang, D.
    Zhang, J.
    Zhang, H.
    Wang, Q.
    Cang, S.
    Li, X.
    Tan, J.
    Xiang, Y.
    Li, X.
    Liu, A.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1693 - S1693
  • [23] Multiple cohort, open-label, exploratory clinical study of trilaciclibe for CIM in combination with chemotherapy in fi rst-line treatment of advanced solid tumors-interim data analysis
    Feng, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1578 - S1578
  • [24] Overall Survival after Treatment with First-Line Osimertinib for EGFR-Mutant Advanced NSCLC in the US
    Sabari, J. K.
    Yu, H. A.
    Mahadevia, P.
    Liu, Y.
    Demirdjian, L.
    Sultan, A. A.
    Chen, Y. H.
    Wang, X.
    Passaro, A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S619 - S620
  • [25] Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib plus /- Radiation Therapy in a Real-World Canadian Cohort
    Litt, I.
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Bebb, G.
    Cheung, W.
    Pabani, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S434 - S434
  • [26] Maintenance durvalumab after fi rst-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study
    Fong, C.
    Patel, B.
    Peckitt, C.
    Bourmpaki, E.
    Satchwell, L.
    Cromarty, S.
    Kidd, S.
    von Loga, K.
    Uhlik, M.
    Begum, R.
    Rana, T.
    Waddell, T.
    Darby, S.
    Bradshaw, A.
    Roques, T.
    Morgan, C.
    Rees, C.
    Herbertson, R.
    Das, P.
    Thompson, C.
    Hewish, M.
    Petty, R.
    Thistlethwaite, F.
    Rao, S.
    Starling, N.
    Chau, I.
    Cunningham, D.
    ESMO OPEN, 2024, 9 (07)
  • [27] Patterns of disease progression and efficacy of local ablative therapy among patients with metastatic EGFR-mutation positive non-small cell lung cancer treated with fi rst-line osimertinib
    Chen, C. C. A.
    Chen, O. H.
    Mok, K.
    Lam, K. C.
    Lee, W. C. K.
    Mok, S. T. F.
    Ng, T. Y. J.
    Johnson, D.
    Chan, L. L.
    Yan, K. C. K.
    Wong, W.
    Lam, B.
    Lee, M. P.
    Mok, T. S. K.
    Li, S. C. M.
    ANNALS OF ONCOLOGY, 2024, 35
  • [28] Furmonertinib 160mg as fi rst-line treatment for metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with central nervous system (CNS) metastases
    Zhang, Y.
    Zeng, L.
    Yang, N.
    Jiang, W.
    Xiong, Y.
    Wang, Z.
    Yang, H.
    Liu, L.
    Zhou, C.
    Zeng, F.
    ANNALS OF ONCOLOGY, 2024, 35
  • [29] The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment
    Zheng, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S646 - S647
  • [30] Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study
    Lee, J. Y.
    Mai, V.
    Garcia, M.
    Cheng, S.
    Khan, K.
    Balaratnam, K.
    Thakral, A.
    Brown, M. C.
    Zhan, L.
    Corke, L.
    Leighl, N.
    Shepherd, F. A.
    Bradbury, P.
    Sacher, A.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S440 - S440
12345